| HOME >> MEDICINE >> TECHNOLOGY |
$ 0.09$ 0.13$ 0.09$ (0.15)Shares used in per share calculationsBasic
146,280144,033145,730143,525Diluted
146,778144,926146,274143,525(1) With the termination of the Lilly collaboration we have revised our non-GAAP presentation to exclude charges and credits relating to the reacquisition of the exenatide product rights, including amortization and interest expense relating to reacquired assets, and have added a new item to reflect an adjustment to GAAP operating loss for the payments we are required to make to Lilly for the promissory note related to the revenue sharing obligation, or 15% of net exenatide sales.AMYLIN PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)December 31,December 31,20112010(unaudited)AssetsCash, cash equivalents and short-term investments
$204,065
$442,663Restricted cash
10,519
15,000Accounts receivable, net
45,489
54,645Inventories, net
111,959
118,629Other current assets
49,158
45,458Property and equipment, net
831,162
811,745Intangible and other assets related
to economic rights reacquired or to be reacquired
601,539
-Other assets
16,308
43,289Total assets
$1,870,199
$1,531,429Liabilities and stockholders' equity Current liabilities
296,017
401,595Other liabilities, net of current portion
292,584
317,654Promissory note related to revenue sharing
obligation, net of current portion
924,306
-Long-term debt
496,037
468,697Stockholders' (deficit)/equity
(138,745)
343,483Total liabilities and stockholders' (deficit)/equity
$1,870,199
$1,531,429
'/>"/>
| SOURCE Amylin Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved |